Transcription of TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) …
{{id}} {{{paragraph}}}
Example: air traffic controller
TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) …
Initial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS) Page 1 of 16 Reference ID: 3677583 I. GOALS The goals of the TIRF REMS Access program are to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: 1. Prescribing and dispensing TIRF medicines only to appropriate patients, which includes use only in opioid-tolerant patients. 2. Preventing inappropriate conversion between TIRF medicines. 3. Preventing accidental exposure to children and others for whom it was not prescribed. 4. Educating prescribers, pharmacists, and patients on the potential for misuse, abuse, addiction, and overdose of TIRF medicines.
Initial REMS approval: 12/2011 Most recent modification: /2014 TRANSMUCOSAL IMMEDIATE RELEASE FENTANYL (TIRF) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: